By Judy Hanover As the market for biosimilars continues to grow, it’s become important for revenue management programs to address these new products in order to build competitive advantage.  [...]

As we close the 2nd quarter of 2020 amidst global economic uncertainty and a pandemic, life sciences companies are facing more change than ever before. In a recent study conducted by Model N, the [...]

Worldwide prescription drug sales reached $843B in 2019, and growth is accelerating with the market expected to grow at a 6% annual CAGR over the next five years.  Yet despite the promise of [...]

MedTech is one of the fastest growing segments of the life sciences industry, with $465B in worldwide sales in 2019, that is expected to grow to $602B by 2024.  MedTech is also one of the fastest [...]

By Erica Bartlett, Product Manager Value-based agreements (VBAs), sometimes called outcomes-based agreements, are on the rise. According to Aetna, it is estimated by 2020 that 75-80% of its [...]

Model N had a fantastic visit this year to the Medicaid Drug Rebate Program Summit (MDRP) in Chicago. It is always a welcomed event to catch up with colleagues, learn from our partners, and [...]

For the Model N life science team, the cancellation of the proposed Safe Harbor Rule change wasn’t just a regulatory decision, it meant we needed to revamp our product planning and initiatives [...]

Medtech revenues have never been higher, and are forecast to reach $595 billion worldwide by 2024, reflecting a CAGR of 5.6% between 2017 and 2024.   Model N counts many medtech manufacturers [...]

The Life Sciences industry is evolving at a faster pace than ever before and drug manufacturers are tasked with managing unprecedented frequency, uncertainty, and complexity of reporting [...]